Q32 Bio Inc

NASDAQ:QTTBUnited States

Q32 Bio Inc. is a clinical-stage biotechnology company. The Company is engaged in developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. Its lead programs, focused on the IL-7 / TSLP receptor pathways and complement system, address immune dysregulation to help patients take back control of their lives. Its program for adaptive immunity, bempikibart (ADX-914), is a fully human anti-IL-7Ra antibody that re-regulates adaptive immune function for the treatment of autoimmune diseases. It is being evaluated in two Phase II trials for the treatment of atopic dermatitis and alopecia areata. Its program for innate immunity, ADX-097, is based on a platform enabling tissue-targeted regulation of the complement system without long-term systemic blockade. The Company has completed a first-in-human, Phase I ascending dose clinical study of ADX-097 in healthy volunteers.

Contact Information

Headquarters

830 Winter StreetWALTHAM, MA, United States 02451

Phone

781-999-0232

Fax

302-655-5049

Executives

Independent Chairman of the Board

Mark Iwicki

President, Chief Financial Officer, Treasurer

Lee Kalowski

Chief Executive Officer, Company Secretary, Director

Jodie Morrison

Chief Scientific Officer and President of Research

Shelia Violette

Chief Medical Officer

Jason Campagna